Debio-4326 is under clinical development by Debiopharm International and currently in Phase III for Central Precocious Puberty. According to GlobalData, Phase III drugs for Central Precocious Puberty does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Debio-4326 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Debio-4326 overview
Debio-4226 is under development for the treatment of central precocious puberty. The drug candidate is an analog of gonadotropin releasing hormone (GnRH). It is administered through intramuscular route.
Debiopharm International overview
Debiopharm International, a subsidiary of Debiopharm Group, focuses on the development and manufacture of drugs for oncology and bacterial infections. The company offers oxaliplatin and triptorelin drugs. It is investigating proteins, peptides and small molecules to treat cancers, solid tumors, bone and joint infections and gastrointestinal disorders. Debiopharm is headquartered in Lausanne, Switzerland.
For a complete picture of Debio-4326’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
